Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISC 2024 | Debating the validity of the ESUS construct

With four trials failing to show the superiority of anticoagulation over antiplatelet therapy for secondary stroke prevention in patients with embolic stroke of undetermined source (ESUS), the validity of the construct is being questioned. Aristeidis Katsanos, MD, McMaster University, Hamilton, Ontario, Canada, comments on what we have learned from studies to date and how the combined data are influencing our understanding of ESUS. This interview took place during the International Stroke Conference 2024 in Phoenix, AZ.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.